Evidence map›Paper›PMID 39007837›Full record

ArticleBiomarkers in medicine2024

A non-enhancing, T2 fluid-attenuated inversion recovery hyperintense, diffusion-restricting brainstem lesion in an EGFR tyrosine kinase inhibitor-treated non-small-cell lung cancer patient.

Carlen A Yuen, Silin Bao, Xiao-Tang Kong

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarkers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carlen A YuenDepartment of Neurology, Neuro-Oncology Division, University of California, Irvine, CA, 92780,USA.ORCID 0000-0003-1950-8819
Silin BaoDepartment of Internal Medicine, Neurosciences Division, Community Regional Medical Center, Fresno, CA 93721, USA.
Xiao-Tang KongDepartment of Neurology, Neuro-Oncology Division, University of California, Irvine, CA, 92780,USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leptomeningeal metastasis (LM) is a devastating complication of malignancy. Diagnosis relies on both contrast enhancement on imaging and malignant cells in cerebral spinal fluid cytology. Though early detection and prompt intervention improves survival, the detection of LM is limited by false negatives. A rare brainstem imaging finding uncovered specifically in

Indexed as

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsProtein Kinase InhibitorsAcrylamidesAgedAniline CompoundsBrain StemDiffusion Magnetic Resonance ImagingFemaleHumansIndolesPyrimidinesTyrosine Kinase InhibitorsAcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesTyrosine Kinase Inhibitorsbrainstemdiffusion restrictionEGFRleptomeningeal carcinomatosisleptomeningeal metastasesMRInon-enhancingnon-small cell lung cancerosimertinibT2 FLAIR hyperintensity

Identifiers

PMID39007837
PMCPMC11285344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.